Inferact’s founding team includes computer science professor and Databricks co-founder Ion Stoica. He is currently the ...

GAH and Tenacia announce a China commercialization partnership for ZTALMY, the first approved therapy for CDKL5 deficiency disorder.

Novel embolic device designed to obstruct or reduce blood flow, Funded by Strategic Investor. DENVER, Oct. 24, 2025 /PRNewswire/ -- Polyembo, a privately held medical device company founded to develop ...

A Cincinnati-based technology company plans to commercialize its technology creating 3D models of X-rays and MRI scans for ...

Please provide your email address to receive an email when new articles are posted on . A Boston-area developer of brain-computer interface technology and a Canadian biotech firm have announced a ...

LG Energy Solution is gearing up to commercialize a cutting-edge battery manufacturing technology that has so far evaded Tesla. It is positioning itself to intensify competition against its Chinese ...

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B) a global leader in life science research and clinical diagnostics products, today announced a collaboration agreement with Oncocyte Corporation (Nasdaq ...

Midtown-based drug discovery startup GRIN Therapeutics has reached a deal with Angelini Pharma to commercialize its signature epilepsy treatment drug outside of North America. The companies announced ...

Please provide your email address to receive an email when new articles are posted on . Povorcitinib is a selective oral Janus kinase 1 inhibitor. China Medical System Holding Limited now has the ...

The agreement with EirGenix grants Sandoz exclusive rights to commercialize proposed biosimilar of pertuzumab for the treatment of HER2-positive early breast cancer. “This agreement underscores our ...

BioLineRx Ltd. (BLRX), a commercial-stage biopharmaceutical company, and Ayrmid Ltd., the parent company of Gamida Cell Ltd (GMDA), have entered into an exclusive license agreement to commercialize ...

Cytokinetics (CYTK) announced that Sanofi (SNY) will acquire exclusive rights to develop and commercialize aficamten from Corxel Pharmaceuticals for the treatment of patients with obstructive and ...